Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 4(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07038837Phase 4Recruiting

Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad

Role: collaborator

NCT06624631Phase 4Recruiting

PDMC Implementation Trial in Kenya

Role: collaborator

NCT04059471Phase 4Completed

Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine

Role: collaborator

NCT04028349Phase 2Completed

ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)

Role: collaborator

All 4 trials loaded